Ixico joins European syndicate to collect data on Alzheimer's

The AIM-listed company is to participate in a new collaborative EU public-private partnership under the innovative medicines initiative umbrella focused on delivering therapies to people with Alzheimer's disease.

For RoadMap, the collaboration with pharmaceutical companies and academics, the company will use its digital technology platforms to devise clinical measurements from biosensors worn by patients, and to develop enhanced models of disease progression to help select appropriate treatments for patients.

Within RoadMap, the company will demonstrate how both approaches can be used in real-world settings, leveraging its existing work in the Cygnus real world evidence study.

Chief executive Derek Hill said: "It provides an excellent opportunity for us to advance our capabilities in wearable biosensors and digital disease models, working collaboratively with leading pharmaceutical companies and academics.

“These are key technologies that are likely to accelerate the approval of and access to beneficial treatments for Alzheimer's disease, and we believe they will provide commercial growth opportunities for Ixico."

This project will enhance the company’s capabilities currently integrated into its TrialTracke and Assessa digital health platforms, which are used by pharmaceuticals both to support development of new treatments and alongside marketed drugs.

This collaboration brings together 22 academic, healthcare and pharmaceuticals, including Novartis Pharma, Eli Lilly and Company, Biogen, F. Hoffman-La Roche, Janssen Pharmaceutica, GE Healthcare and AC Immune.

Shares in Ixico were up 0.82% to 24.70p at 1006 GMT.